Press release
Orthofix Announces First Patient Implant in the M6-C Artificial Cervical Disc Two-Level IDE Study
Study will evaluate patients treated for cervical degenerative disc disease at two contiguous vertebral levels with the M6-C disc compared to ACDF
About this update from Orthofix Medical Inc.
[{"type":"text","content":"\nStudy will evaluate patients treated for cervical degenerative disc disease at two contiguous vertebral levels with the M6-C disc compared to ACDF\n\n LEWISVILLE, Texas--(BUSINESS WIRE)--\nOrthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced the first patient implant in a U.S. Food and Drug Administration (FDA) clinical study that will evaluate the safety and effectiveness of the M6-C™ artificial cervical disc compared to anterior cervical discectomy and fusion (ACDF) for the treatment of contiguous two-level symptomatic cervical radiculopathy.\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210802005105/en/Image of the Orthofix M6-C™ artificial cervical disc (Photo: Business Wire)\n“Artificial cervical disc replacement is rapidly becoming the standard of care for patients suffering from degenerative cervical disc disease because it preserves motion, unlike ACDF procedures,” said Dr. Todd Lanman, a spinal neurosurgeon with Beverly Hills-based Lanman Spinal Neurosurgery and founder of the national ADR Advanced Disc Replacement Spinal Restoration Center who performed the first patient implant in the study. “The M6-C artificial cervical disc two-level study will provide additional data to validate the effectiveness of disc replacement over fusion in patients suffering from degeneration in two contiguous levels.”\n\nBeing conducted under a U.S. Investigational Device Exemption (IDE), the study will evaluate the safety and effectiveness of the M6-C artificial cervical disc compared to ACDF for the treatment of contiguous two-level symptomatic cervical radiculopathy at vertebral levels from C3 to C7 with or without spinal cord compression.\n\nPatients will be concurrently enrolled in the M6-C treatment group and the ACDF control group. For the study, 263 patients will undergo either a two-level cervical artificial disc procedure or an instrumented ACDF procedure as per site group assignment. Patients will be evaluated clinically, radiographically, and via the collection of patient-reported outcomes at six weeks, three months, six months, 12 months and 24 months. The primary endpoint is overall success at 24 months.\n\n“To date there have been more than 55,000 implantations worldwide of the M6-C artificial...